Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2024-08-21 00:00:00 ET · period of report 2024-08-19 · accession 0000950170-24-099481 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-21 | 2024-08-19 | TRVI | SCIASCIA THOMAS | CSO | M - OptEx | $1.43 | +16.5K | 236.8K | +7% | +$23.6K |
| D | 2024-08-21 | 2024-08-19 | TRVI | SCIASCIA THOMAS | CSO | S - Sale+OE | $2.96 | -16.5K | 220.3K | -7% | -$48.8K |
| D | 2024-08-21 | 2024-08-19 | TRVI | SCIASCIA THOMAS | CSO | M - OptEx | $0.00 | -16.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-19 | M | A | 16,496 | $1.43 | 236,811 | D | — | — | |
| 2 | Common | Common Stock | 2024-08-19 | S | D | 16,496 | $2.96 | 220,315 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9000 to $3.0020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 3 | Derivative | Stock Option (right to buy) | 2024-08-19 | M | D | 16,496 | $0.00 | 0 | D | $1.43 · — to 2024-11-24 | 16,496 Common Stock | (F2) This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018. |